BIIB News 297.98 04/21/2014 20:01:21 Biogen Idec Inc (BIIB)
Post# of 273249
Posted On: 04/21/2014 9:01:23 PM
Biogen Idec Inc (BIIB) 297.98 $BIIB
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - 2 hrs 31 mins ago
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 41 mins ago
Amgen has an Earnings ESP of 0.00% with a Zacks Rank #1 (Strong Buy).
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 2.56% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:12PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:11PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 9:50AM CDT
Gilead is set to report first quarter 2014 results on Apr 22 after the market closes
Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
Marketwire - Mon Apr 21, 7:02AM CDT
Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. Under the terms of the option agreement, Amunix will receive an upfront $1 million payment and will also be eligible to receive up to $38 million in clinical and commercial milestone payments. In addition, royalties will be paid on commercial sales by Biogen Idec for Factor VIII products incorporating Amunix proprietary XTEN technology.
Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 1:05PM CDT
Here at The Motley Fool we spend a lot of time dissecting companies at the leading edge of the largest investment opportunities. Being a specialist in the Health Care sector, that means I devote a lot of my research to drugs aimed at treating some of...
This Medical Marijuana Stock Is Not What You Think
Brian Orelli, The Motley Fool - Motley Fool - Sat Apr 19, 12:30PM CDT
Despite its research into marijuana, GW Pharmaceuticals isn't going to run into legal troubles. Unlike many of the medical-marijuana companies producing and selling marijuana in states where it's legal, GW Pharmaceuticals isn't stuck in limbo...
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 2.10% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 2.10% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...
'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.
RBCC Bioprinting Partner Expands Brand Awareness Campaign
Business Wire - Wed Apr 16, 3:28AM CDT
Rainbow Coral Corp.'s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.
Health Care Stocks: Check Out This Low-Cost Market Beater
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 15, 4:15PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF ...
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's...
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - 2 hrs 31 mins ago
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 41 mins ago
Amgen has an Earnings ESP of 0.00% with a Zacks Rank #1 (Strong Buy).
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 2.56% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:12PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:11PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 9:50AM CDT
Gilead is set to report first quarter 2014 results on Apr 22 after the market closes
Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
Marketwire - Mon Apr 21, 7:02AM CDT
Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. Under the terms of the option agreement, Amunix will receive an upfront $1 million payment and will also be eligible to receive up to $38 million in clinical and commercial milestone payments. In addition, royalties will be paid on commercial sales by Biogen Idec for Factor VIII products incorporating Amunix proprietary XTEN technology.
Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 1:05PM CDT
Here at The Motley Fool we spend a lot of time dissecting companies at the leading edge of the largest investment opportunities. Being a specialist in the Health Care sector, that means I devote a lot of my research to drugs aimed at treating some of...
This Medical Marijuana Stock Is Not What You Think
Brian Orelli, The Motley Fool - Motley Fool - Sat Apr 19, 12:30PM CDT
Despite its research into marijuana, GW Pharmaceuticals isn't going to run into legal troubles. Unlike many of the medical-marijuana companies producing and selling marijuana in states where it's legal, GW Pharmaceuticals isn't stuck in limbo...
Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...
AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 2.10% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 2.10% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...
'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.
RBCC Bioprinting Partner Expands Brand Awareness Campaign
Business Wire - Wed Apr 16, 3:28AM CDT
Rainbow Coral Corp.'s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.
Health Care Stocks: Check Out This Low-Cost Market Beater
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 15, 4:15PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF ...
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's...
(0)
(0)Scroll down for more posts ▼